Tumor immunity landscape in non-small cell lung cancer
Even with the great advances in immunotherapy in recent years, the response rate to immune checkpoint inhibitor therapy for non-small cell lung cancer is only about 20%. We aimed to identify new features that would better predict which patients can benefit from an immune checkpoint blocker. This stu...
Main Authors: | Xiaoqing Yu, Xuefeng Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
PeerJ Inc.
2018-03-01
|
Series: | PeerJ |
Subjects: | |
Online Access: | https://peerj.com/articles/4546.pdf |
Similar Items
-
Benchmarking HLA genotyping and clarifying HLA impact on survival in tumor immunotherapy
by: Xiangyong Li, et al.
Published: (2021-07-01) -
Correlate tumor mutation burden with immune signatures in human cancers
by: Xiaosheng Wang, et al.
Published: (2019-01-01) -
Immune Cytolytic Activity as an Indicator of Immune Checkpoint Inhibitors Treatment for Prostate Cancer
by: Ze Gao, et al.
Published: (2020-08-01) -
Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
by: Hao Chen, et al.
Published: (2019-05-01) -
Corrigendum: Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
by: Hao Chen, et al.
Published: (2019-07-01)